Abstract:Abstract Vulval intraepithelial neoplasia (VIN) is a premalignant change of the vulval epithelium that can progress to squamous cell carcinoma (SCC). Immunosuppressed patients are a high-risk subset, with a greater risk of recurrence with standard treatment. To date, there is limited research focusing on this vulnerable population. A retrospective study was designed to review the treatment outcomes of immunosuppressed patients with VIN in a tertiary, multidisciplinary vulval service. In total, 104 biopsy-proven adults with VIN were identified from a histological database from 1 April 2013 to 31 March 2023. Patient demographic data, disease type and treatment outcome were collected. Electronic records and medical photography, where available, were used to retrospectively map each vulval lesion in quadrants. Complete response (CR) was defined as being clinically and/or pathologically clear of disease at 3 months’ follow-up. Recurrence was defined as lesions reappearing in the same quadrant after achieving CR. Data analyses were performed using IBM SPSS Statistics for univariate analyses. Overall, 31 of 104 patients (30%) were immunosuppressed, developing 47 lesions in the study period. This was due to HIV (n = 9), diabetes (n = 5), active malignancy (n = 10) and other causes (n = 7). The mean age was 54 years (range 20–94) with a mean follow-up duration of 70 months (range 11–132). The histological subtypes of VIN included low-grade squamous intraepithelial lesion (11%), high-grade squamous intraepithelial lesion (72.3%), differentiated VIN (4.3%) and microinvasive SCC (14.9%). Immunosuppressed patients were more likely to have multifocal disease (57.4% vs. 29.8%, P = 0.003) with previous human papillomavirus (HPV) burden (66.7% vs. 36.6%, P = 0.008). For those screened during the study period, immunosuppressed patients were more likely to have associated anal intraepithelial neoplasia (25.8% vs. 6.9%, P = 0.02) and cervical intraepithelial neoplasia (29.0% vs. 15.2%, P = 0.031). The CR rate from first-line treatment (imiquimod, surgery, laser or PlasmaJet®) was 54.8% in the immunosuppressed cohort compared with 75.6% in the control group (P = 0.073). There was no difference in the rate of recurrence or progression to SCC. There was no death due to disease observed in the immunosuppressed group, compared with three patients in the control group. In summary, our high-risk population with VIN was found to have a higher burden of HPV and was more likely to have multicentric disease. The treatment outcome was noninferior to the control group’s, unlike similar previous case series. This highlights the need for multidisciplinary clinics offering long-term close monitoring, with early treatment and HPV surveillance.

Therapeutic effect and safety evaluation on 5% imiquimod cream in the treatment of vulva intraepithelial neoplasia

Topical Treatment of All-Trans Retinoic Acid Cream Combined with Penciclovir Cream for Verruca Plana: A Multiple Centre,double-Blind and Control Study

High-Intensity Focused Ultrasound Treatment for Non-Neoplastic Epithelial Disorders of the Vulva

Recurrent vaginal intraepithelial neoplasia successfully treated with topical imiquimod: A case report

The curative effect of HIFU on patients with vulvar intraepithelial nonneoplasia

Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis

Efficacy and Safety of Photodynamic Therapy Mediatied by 5-Aminolevulinic Acid for the Treatment of Vaginal High-Grade Intraepithelial Lesions.

Evaluation of Topical 5% Imiquimod Cream on the Treatment of Condylomata Acuminata

Imiquimod 5% Cream for the Treatment of External Anogenital Warts: a Randomised Controlled Study

A New Incorporative Therapeutic Method for Nonneoplasia Epithelial Disorders of Skin and Mucosa of Vulva

Imiquimod 5% cream for the treatment of external anogenital warts:a randomised controlled study

Efficacy and Safety of 5-Aminolevulinic Acid Photodynamic Therapy for Treating Cervical and Vaginal Intraepithelial Neoplasia

Vulvar squamous intraepithelial neoplasia epithelial thickness in hairy and non-hairy sites: a single center experience from China

Clinical Features, Treatment and Outcomes of Vaginal Intraepithelial Neoplasia in a Chinese Tertiary Centre

Efficacy and influencing factors of CO2 laser, topical photodynamic therapy versus therapy combined with CO2 laser pretreatment for vaginal low-grade squamous intraepithelial lesions with high-risk HPV infection

[Preliminary Study of Vulvar and Vaginal Intraepithelial Neoplasias].

Poster presentationsBI18 The management of vulval intraepithelial neoplasia in immunosuppressed women: outcome and recommendations from a multidisciplinary vulval clinic

Observation of Topical Application with 5% Imiquimod Cream on Condyloma Acuminata Relapse Prevention

Evaluation of 5-aminolevulinic acid-mediated photodynamic therapy in postmenopausal women with persistent HPV infection with or without cervical and vaginal low-grade squamous intraepithelial lesions (CIN1/VaIN1)

A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma.

Treatment of Condyloma Acuminatum with Imiquimod Cream:A Randomized, Double-blind, Place-bo-controlled, Multi-central Clinical Trial